Home > Haematology > ASH 2019 > Inclusive Medicine > ALCYONE: New overall survival results for myeloma

ALCYONE: New overall survival results for myeloma

Presented By
Dr Maria Victoria Mateos, University Hospital of Salamanca, Spain
ASH 2019
Phase 3, ALCYONE
Dr Maria Victoria Mateos (University Hospital of Salamanca, Spain) presented the updated efficacy and safety results from a prespecified, interim analysis of the phase 3 ALCYONE study with over 40 months of follow-up, demonstrating improved overall survival when daratumumab is added to frontline treatment [1,2]. ALCYONE was a multicentre, randomised, open-label, active-controlled, phase 3 trial that enrolled 706 newly diagnosed multiple myeloma patients, who were ineligible for high-dose chemotherapy with autologous stem-cell transplantation, because of their age (≥65 years) or because of substantial comorbidities. Patients were randomly assigned to receive daratumumab in combination with bortezomib, melphalan, and prednisone (D-VMP; n=350) or bortezomib, melphalan, and prednisone (VMP; n=356). Patient baseline characteristics were well balanced between treatment arms....

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on